Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$10.62 USD
-0.23 (-2.12%)
Updated Aug 1, 2024 04:00 PM ET
After-Market: $10.63 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ROIV 10.62 -0.23(-2.12%)
Will ROIV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ROIV
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stock Market News for Nov 14, 2023
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?
Other News for ROIV
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
3 Best Stocks to Buy Now, 7/19/2024, According to Top Analysts
Piper Sandler Keeps Their Buy Rating on Roivant Sciences (ROIV)
Buy Rating on Roivant Sciences Amid Anticipation of High-Potential Phase 2 Asset Reveal
Tracking Baker Brothers Portfolio - Q1 2024 Update